 |
KaloBios Reports Top-Line Data for Phase 2 Study of KB001-A to Treat Pseudomonas Aeruginosa Lung Infections in Cystic Fibrosis Patients
Jan 6, 2015
|
32.8 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Jan. 6, 2015 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced top-line data from the randomized, double-blind, placebo-controlled Phase 2 study of KB001-A, an anti-PcrV monoclonal antibody (mAb) fragment, to treat Pseudomonas aeruginosa (Pa) lung infections in subjects with cystic fibrosis (...
|
|
KaloBios Elects Robert A. Baffi, BioMarin Senior Executive, to Board of Directors
Dec 1, 2014
|
29.2 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Dec. 1, 2014 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced the election of Robert A. Baffi, Ph.D. to the KaloBios Board of Directors. Dr. Baffi is Executive Vice President of Technical Operations at BioMarin Pharmaceutical Inc. (Nasdaq: BMRN).
"Robert Baffi is a long-time vete...
|
|
KaloBios Announces Upcoming Scientific and Investor Conference Participation
Nov 11, 2014
|
30.2 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2014 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that it will present at the Stifel 2014 Healthcare Conference in November, and that data on the company's KB004 program in hematologic malignancies will be presented in a poster session at the 56th American Society of Hematology ...
|
|
KaloBios Reports Third Quarter Financial Results
Nov 6, 2014
|
35.6 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Nov. 6, 2014 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today reported its financial results for the third quarter of 2014.
Net loss for the three months ended September 30, 2014 was $8.1 million or $0.24 per common share, as compared to $11.3 million or $0.47 per common share for the same...
|
|
Publication by KaloBios and Collaborators Shows EphA3 as Target for Highly Selective Anticancer Therapy
Aug 14, 2014
|
29.8 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Aug. 14, 2014 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced the publication of preclinical findings describing EphA3 as a novel target expressed by a broad range of human tumors, and whose activation can lead to the selective disruption of the tumor microenvironment and newly formed tumo...
|
|
KaloBios Provides Clinical Update and Reports Second Quarter Financial Results
Aug 7, 2014
|
36.7 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Aug. 7, 2014 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today provided an update on its current clinical programs and announced financial results for the second quarter of 2014.
Development Program UpdatesKB004KaloBios completed enrollment in July in the open-label Phase 1 dose escalation ...
|
|
KaloBios Provides Update on KB001-A Partnership and Clinical Status
Jul 28, 2014
|
31.9 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., July 28, 2014 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today provided an update on the status of the KB001-A development program, including an update on its KB001-A collaboration with Sanofi Pasteur.
KB001-A Collaboration Update KaloBios announced that it has reached an agreement with S...
|
|
KaloBios to Present at 9th Annual JMP Securities Healthcare Conference
Jun 11, 2014
|
35.8 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., June 11, 2014 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that the company will be presenting at the following investor conference:
The 9th Annual JMP Securities Healthcare Conference
Date:
Wednesday, June 25, 2014
Time:
...
|
|
KaloBios to Present at Jefferies 2014 Global Healthcare and BBC Boston CEO Conferences
May 21, 2014
|
36.0 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., May 21, 2014 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that the company will be presenting at the following investor conferences:
Jefferies 2014 Global Healthcare ConferenceTuesday, June 3, New York City, NYCorporate Presentation by KaloBios President & CEO David Pritchard,...
|
|
KaloBios Provides First Quarter 2014 Financial Results
May 8, 2014
|
36.4 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., May 8, 2014 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced financial results for the first quarter of 2014 and provided an update on its current clinical programs and timelines.
Development Program Updates
KB001-AEnrollment in the Phase 2 study in cystic fibrosis (CF) pa...
|
|
Ted W. Love, M.D., Named Chairman of the Board of KaloBios
May 6, 2014
|
27.6 KB |
|
| |
SOUTH SAN FRANCISCO, May 6, 2014 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that the company's board of directors has elected Ted W. Love, M.D., as the Chairman, effective May 1, 2014. Dr. Love succeeds James I. Healy, M.D., Ph.D., who had served as a member of the board of directors and as chairman of the board ...
|
|
KaloBios Announces Upcoming Participation at Needham Healthcare Conference
Apr 3, 2014
|
35.7 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., April 3, 2014 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that the company will be presenting at the following upcoming investor conference:
13th Annual Needham Healthcare Conference Tuesday, April 8, 2014 at the Westin Grand Central Hotel in New York City, NY 11:20AM - ...
|
|
KaloBios Announces Fiscal Year 2013 Financial Results
Mar 13, 2014
|
36.4 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., March 13, 2014 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today provided an update on corporate accomplishments in fiscal 2013 and key milestones for 2014 as well as announcing financial results for fiscal year 2013.
Fiscal 2013 Accomplishments
Key corporate accomplishments during fisc...
|
|
KaloBios Announces Upcoming Participation at ROTH and BioCentury's Future Leaders in the Biotech Industry Conferences
Mar 10, 2014
|
28.4 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., March 10, 2014 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that the company will be presenting at the following upcoming investor conferences:
26th Annual ROTH ConferenceWednesday, March 12, 2014 in Laguna Niguel, California8:00 - 8:30 AM Pacific Time
BioCentury's Future ...
|
|
KaloBios Initiates Phase 2 Expansion Portion of Study of KB004 in Hematologic Malignancies
Feb 11, 2014
|
14.8 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Feb. 11, 2014 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that the company has begun treating patients in the Phase 2 expansion portion of study KB004-01 evaluating KB004, the company's anti-EphA3 Humaneered® monoclonal antibody (mAb). The company is targeting enrollment of 30 pati...
|
|
KaloBios Announces Upcoming Webcasts and Conference Participation
Feb 5, 2014
|
14.7 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Feb. 5, 2014 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that David Pritchard, President and Chief Executive Officer, will be presenting at the following upcoming investor conferences:
16th Annual BIO CEO & Investor ConferenceTuesday, February 11, 2014 in New York City8:30 AM...
|
|
KaloBios Reports Top-Line Data for Phase 2 Study of KB003 in Severe Asthma
Jan 29, 2014
|
62.8 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Jan. 29, 2014 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced the completion of the randomized, double-blind placebo-controlled Phase 2 study of KB003, its anti-GM-CSF monoclonal antibody (mAb), in patients with severe asthma. While the study showed that KB003 was generally safe and well to...
|
|
Epidemiological Study on Ventilator-Associated Pneumonia Incidence Reported at Critical Care Congress, Announces KaloBios
Jan 13, 2014
|
16.4 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Jan. 13, 2014 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced the presentation of epidemiological research sponsored by Sanofi Pasteur, KaloBios' exclusive licensee for KB001-A, estimating the incidence of Pseudomonas aeruginosa Ventilator Associated Pneumonia (Pa-VAP) in at-risk patients r...
|
|
KaloBios Appoints Harry Lam, Ph.D. as Head of Manufacturing
Jan 7, 2014
|
14.3 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Jan. 7, 2014 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced the appointment of Harry Lam, Ph.D. as Head of Manufacturing. Dr. Lam brings to KaloBios more than 28 years of experience in biopharmaceutical manufacturing, including 17 years at Genentech, where he ultimately served as Global He...
|
|
KaloBios Announces Preliminary Phase 1 Results in Advanced Hematologic Malignancies with KB004, an Anti-EphA3 Monoclonal Antibody
Dec 10, 2013
|
15.3 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Dec. 10, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced preliminary results of an ongoing multi-center Phase 1 study of KB004, an anti-EphA3 monoclonal antibody (mAb), which the company is developing as a treatment for hematologic malignancies. Forty-four patients with refractory dise...
|
|
|
Delicious
Digg
Facebook
LinkedIn
Twitter